Market closed
Kyverna Therapeutics/$KYTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Ticker
$KYTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
119
Website
KYTX Metrics
BasicAdvanced
$125M
-
-$3.99
-
-
Price and volume
Market cap
$125M
52-week high
$30.60
52-week low
$2.65
Average daily volume
415K
Financial strength
Current ratio
10.501
Quick ratio
10.379
Long term debt to equity
1.719
Total debt to equity
3.018
Interest coverage (TTM)
-741.60%
Management effectiveness
Return on assets (TTM)
-34.79%
Return on equity (TTM)
-59.58%
Valuation
Price to book
0.41
Price to tangible book (TTM)
0.41
Price to free cash flow (TTM)
-0.822
Growth
Earnings per share change (TTM)
-94.97%
What the Analysts think about KYTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.
KYTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KYTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KYTX News
AllArticlesVideos
Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX
Accesswire·3 weeks ago
Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX
GlobeNewsWire·3 weeks ago
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kyverna Therapeutics stock?
Kyverna Therapeutics (KYTX) has a market cap of $125M as of February 26, 2025.
What is the P/E ratio for Kyverna Therapeutics stock?
The price to earnings (P/E) ratio for Kyverna Therapeutics (KYTX) stock is 0 as of February 26, 2025.
Does Kyverna Therapeutics stock pay dividends?
No, Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Kyverna Therapeutics dividend payment date?
Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) does not currently have a Beta indicator.